F2G has announced the appointment of Dr Patrick Vink as chairman of the Board of Directors with immediate effect. He replaces Dr Richard J. White who stood down in December 2018.
Dr Vink has over 30 years of experience in the biotechnology and pharmaceutical industry and has a successful track record of building and growing global pharmaceutical businesses. He was previously chief operating officer at Cubist Pharmaceuticals Inc, with responsibility for global commercial operations, and the development and implementation of long and short-term strategy.
He is currently on the board of several US and European publicly listed and private companies including Chairman of Acacia Pharma, Targovax and NMD Pharma and non-executive director of Spero Therapeutics, Arch Biopartners and Santhera AG.
Ian Nicholson, CEO of F2G Ltd, commented on the appointment: “We are delighted to welcome Patrick to the Board. During his career, he has been responsible for several successful new product launches and held senior roles overseeing R&D, commercial and technical operations. His breadth and depth of experience will be invaluable as we accelerate the development of our lead candidate olorofim as a treatment for rare invasive fungal infections. On behalf of the Board of Directors I would like to thank Richard for his dedication, commitment and steadfast leadership during the evolution of F2G from discovery to late stage clinical development.”